666 results on '"Cibula D."'
Search Results
2. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
3. Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe
4. Quality of life after extended pelvic exenterations
5. Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis
6. Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement: ABRAX international retrospective cohort study
7. Doporučené postupy klinické péče o nosiče zárodečných mutací v genech BRCA1, BRCA2, PALB2, ATM a CHEK2 predisponujících ke vzniku dědičného karcinomu prsu, vaječníků, prostaty a pankreatu (4...
8. Doporučené postupy klinické péče o nosiče zárodečných mutací v genech MLH1, MSH2, MSH6, PMS2 a velkých delecí EPCAM predisponujících ke vzniku Lynchova syndromu (4.2024).
9. Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial
10. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
11. SLN biopsy in cervical cancer patients with tumors larger than 2 cm and 4 cm
12. Pelvic floor reconstruction by modified rectus abdominis myoperitoneal (MRAM) flap after pelvic exenterations
13. Risk of micrometastases in non-sentinel pelvic lymph nodes in cervical cancer
14. SUCCOR Nodes: May Sentinel Node Biopsy Determine the Need for Adjuvant Treatment?
15. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
16. MANAGEMENT OF PREGNANCY AFTER FERTILITY-SPARING SURGERY FOR CERVICAL CANCER: EP683
17. CLINICAL AND ULTRASOUND FEATURES OF EXTRA GASTROINTESTINAL STROMAL TUMORS (EGIST): EP447
18. SENTIX - SENTINEL LYMPH NODES IN PATIENTS WITH CERVICAL CANCER: SLN DETECTION AND THE FALSE NEGATIVE RATE OF SLN FROZEN SECTION (CEEGOG-CX01; ENGOT-CX2; NCT02494063): EP334
19. Preoperative staging of advanced ovarian cancer: comparison between ultrasound, computed tomography (CT) and whole-body MRI with diffusion-weighted sequence (WB-DWI/MRI)
20. The efficacy of an algorithm using sentinel lymph node biopsy and frozen section in the avoidance of a combined treatment in early-stage cervical cancer management
21. Diagnostic performance of ultrasound in the assessment of parametrial involvement before surgery in cervical cancer patients (diagnostic accuracy study)
22. SENTIX - Sentinel lymph node in patients with cervical cancer: time to voiding recovery after surgery (CEEGOG-CX01; ENGOT-CX2; NCT02494063)
23. SUCCOR study. An international european cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 (FIGO 2009, <4 cm) cervical cancer operated in 2013-2014
24. 33 Olaparib monotherapy versus (VS) chemotherapy for germline BRCA-mutated (GBRCAM) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (PTS): phase III solo3 trial
25. 22 Open vs. minimally invasive radical trachelectomy in early stage cervical cancer: international multicenter irta study results
26. 21TiP Molecular alterations predictive of outcome in early staged cervical cancer: A translational investigation in the international validation study of sentinel node biopsy in early cervical cancer SENTICOL III
27. Imaging in gynecological disease (26): clinical and ultrasound characteristics of benign retroperitoneal pelvic peripheral‐nerve‐sheath tumors.
28. SUCCOR cone study
29. High false negative rate of frozen section examination of sentinel lymph nodes in patients with cervical cancer
30. 793TiP A phase III, randomized, open-label, multicenter study of sacituzumab tirumotecan (sac-TMT) monotherapy vs treatment of physician’s choice chemotherapy in patients with endometrial cancer who have received prior chemotherapy and immunotherapy: ENGOT-en23/GOG-3095/MK-2870-005
31. Accuracy of ultrasound in prediction of rectosigmoid infiltration in epithelial ovarian cancer
32. Sentinel lymph node status in patients with locally advanced cervical cancers and impact of neoadjuvant chemotherapy
33. Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer
34. VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer
35. New classification system of radical hysterectomy: Emphasis on a three-dimensional anatomic template for parametrial resection
36. Ultrasound in preoperative assessment of pelvic and abdominal spread in patients with ovarian cancer: a prospective study
37. Bone quality assessment in type 2 diabetes mellitus
38. Late morbidity following nerve-sparing radical hysterectomy
39. Pelvic lymphadenectomy in cervical cancer—surgical anatomy and proposal for a new classification system
40. Sentinel node (SLN) biopsy in the management of locally advanced cervical cancer
41. SURVIVAL AFTER RECURRENCE IN EARLY-STAGE CERVICAL CANCER PATIENTS
42. SENSITIVITY AND FALSE NEGATIVITY OF SLN FROZEN SECTIONHISTOLOGICAL EVALUATION IN THE SENTIX TRIAL (CEEGOG-CX01; ENGOT-CX2; NCT02494063)
43. Factors affecting sonographic preoperative local staging of endometrial cancer
44. Randomized phase III trial on niraparib - TSR-042 (dostarlimab) vs physician's choice CHEmotherapy in recurrent ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
45. Perspectives, fears and expectations of patients with gynaecological cancers during the COVID-19 pandemic: A Pan-European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe)
46. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer:Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study
47. 750P PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial
48. 747MO First results from the ENGOT-GYN2/GOG-3051/BOUQUET phase II biomarker-directed platform study: Cobimetinib (cobi) or atezolizumab (atezo) + bevacizumab (bev) for persistent/recurrent rare epithelial ovarian cancer (eOC)
49. 740MO Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
50. Efficacy and Safety of a Low-Dose 21-Day Combined Oral Contraceptive Containing Ethinylestradiol 20μg and Drospirenone 3mg
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.